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Background: The large airways of the lungs (trachea and bronchi) are lined with a pseudostratified mucociliary
epithelium, which is maintained by stem cells/progenitors within the basal cell compartment. Alterations in basal
cell behavior can contribute to large airway diseases including squamous cell carcinomas (SQCCs). Basal cells have
traditionally been thought of as a uniform population defined by basolateral position, cuboidal cell shape, and
expression of pan-basal cell lineage markers like KRT5 and TP63. While some evidence suggests that basal cells are
not all functionally equivalent, few heterogeneously expressed markers have been identified to purify and study
subpopulations. In addition, few signaling pathways have been identified that regulate their cell behavior. The goals
of this work were to investigate tracheal basal cell diversity and to identify new signaling pathways that regulate
basal cell behavior.
Methods: We used flow cytometry (FACS) to profile cell surface marker expression at a single cell level in primary
human tracheal basal cell cultures that maintain stem cell/progenitor activity. FACS results were validated with tissue
staining, in silico comparisons with normal basal cell and lung cancer datasets, and an in vitro proliferation assay.
Results: We identified 105 surface markers, with 47 markers identifying potential subpopulations. These subpopulations
generally fell into more (~ > 13%) or less abundant (~ < 6%) groups. Microarray gene expression profiling supported
the heterogeneous expression of these markers in the total population, and immunostaining of large airway tissue
suggested that some of these markers are relevant in vivo. 24 markers were enriched in lung SQCCs relative to
adenocarcinomas, with four markers having prognostic significance in SQCCs. We also identified 33 signaling receptors,
including the MST1R/RON growth factor receptor, whose ligand MST1/MSP was mitogenic for basal cells.
Conclusion: This work provides the largest description to date of molecular diversity among human large airway basal
cells. Furthermore, these markers can be used to further study basal cell function in repair and disease, and may aid in
the classification and study of SQCCs.* Correspondence: nadeem.moghal@uhnresearch.ca
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The primary function of the lungs is to deliver oxygen to
blood and remove carbon dioxide. This occurs by the
conduction of air from the larger airways (e.g. trachea,
bronchi, and bronchioles) to the smaller alveoli where
gas exchange occurs with the pulmonary capillaries. To
perform this function, the airways are lined with distinct
specialized epithelia in different anatomical segments.
The nasopharyngeal, tracheal, and bronchial epithelia
(tracheobronchial epithelia) are similar and have a cel-
lular composition that prevents infection from inhaled
particles and microorganisms. Secretory cell types within
this epithelium produce an air surface liquid, which
traps microorganisms and is expelled by the coordinated
beating of cilia on ciliated cells. Abnormalities in the re-
generation of this epithelium contribute to the patho-
genesis of large airway diseases such as COPD, asthma,
cystic fibrosis, and squamous cell carcinomas.
The tracheobronchial epithelium is derived from basal
cells, which are marked by CD44, KRT5, and the TP63
transcription factor [1-4]. In mice, lineage tracing of
KRT5-expressing cells indicates these cells self-renew
and give rise to secretory and ciliated cells [5]. These
findings are also supported by KRT14 lineage tracing,
which marks a subset of basal cells [6,7]. Similarly, when
analyzed in vivo in denuded rat tracheas, human tracheal
basal cells generate secretory and ciliated cells, but also
give to rise to submucosal glands beneath the surface
epithelium [8]. In addition, in vitro, clonally expanded
TP63-positive human tracheobronchial basal cells dif-
ferentiate into secretory and ciliated cells when grown
under air-liquid-interface culture conditions [9]. Whe-
ther all TP63-positive basal cells have equivalent stem/
progenitor activity and what are the signals that regulate
their self-renewal and differentiation are major questions
in large airway stem cell biology. In rat tracheal xeno-
grafts, individual human tracheobronchial basal cells
generate different numbers of progeny with distinct
combinations of basal, ciliated, goblet, and submucosal
gland cells, suggesting heterogeneity in function [8].
Some of these differences may track with differences in
aldehyde dehydrogenase activity, which varies among
basal cells and correlates with better growth in vitro
[10]. Similarly, murine tracheal basal cells may also be
functionally heterogeneous, with some KRT5-expressing
cells growing better than others in vitro [5]. In this setting,
KRT14 appears to be another marker of heterogeneity
since KRT5/KRT14-double positive cells are a minor
population in the normal epithelium, but become abun-
dant after injury [11-13].
Whether functionally distinct responses of individual
basal cells arise stochastically, hierarchically, or from
environmentally-regulated differences in cell state is not
known. There has been little phenotypic characterizationof basal cell diversity, and distinct subsets of molecularly-
defined basal cells have generally not been purified to
homogeneity. Studies of basal cell diversity have been
hampered by difficulties with in vivo studies, potential
species-specific differences in basal cell properties, and a
lack of tools. Certain basal cell subpopulations might be
rare under normal uninjured conditions, and in general,
tissue antibody staining can be problematic. Furthermore,
the compositions of the tracheobronchial epithelia are not
identical between humans and all animals. As compared
to mice, human large airways have more goblet cells, and
basal cells and submucosal glands extend more distally;
while murine large airways have abundant Clara cells, a
secretory cell type that is confined to bronchioles in
humans [14-17]. These observations suggest that basal
cells might have species-specific differences in lineage po-
tential and/or regulation, which is supported by compari-
sons of their transcriptomes [18]. Indeed, there appears to
be differences in expression of keratins, integrins, develop-
mental transcription factors (e.g. FOX family, SOX family,
HMG family) and signaling molecules (e.g. Wnt family)
between human and murine basal cells.
To date, only a small number of soluble factors have
been identified that regulate human tracheobronchial
basal cell proliferation and differentiation. EGF, insulin,
and FGF7 are mitogens for basal cells [19-22], while
TFF3 stimulates ciliogenesis and IL-4 and IL-13 promote
mucinous differentiation [23-25]. Retinoic acid (RA)
promotes differentiation both of ciliated and mucinous
cell types [26,27]. Here, we performed the first large
scale profiling of cell surface marker expression at a sin-
gle cell level in primary cultures of human tracheal basal
cells. We found 105 markers that were expressed on all
tested isolates of basal cells, with 47 markers partition-
ing basal cells into subpopulations of different sizes. The
expression of some markers was confirmed on basal
cells in vivo. Furthermore, 24 markers were enriched in
lung squamous cell carcinomas (SQCCs) relative to
adenocarcinomas, and four markers had significant asso-
ciations with overall survival for SQCC patients. Finally,
we found that the MST1R/RON receptor tyrosine kinase
is expressed on all basal cells, and identified its ligand
MST1/MSP, as a new mitogen for tracheobronchial basal
cells. These cell surface markers will now allow the puri-
fication and study of molecularly-defined subsets of hu-
man basal cells, identify new signaling pathways that
may regulate proliferation and differentiation, and may
also aid in the classification and study of SQCCs.
Methods
Ethics statement and human tracheal tissue
Normal human tracheal tissue was obtained as surgical
waste from lung transplant operations with written in-
formed consent from lung donors, and with the approval
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(study 08-0318-T). The tracheal tissue was healthy and
was obtained from lungs deemed to be of suitable
quality for lung transplants, but was not necessary for
the transplant procedure. For high throughput antibody
screening, the three strains of basal cells were derived
from patients with the following characteristics: Strain
23 (age 47, male, non-smoker), Strain 38 (age 59, male,
non-smoker), and Strain 37 (age 38, male, non-smoker).
The 8227 leukemic cell line was derived from a pri-
mary human AML with written informed consent from
the donor, and with approval of the University Health
Network Research Ethics Board (study 02-0763-C).
Isolation of human tracheal epithelial cells
Basal cells were isolated following the procedure of
Karp et al. [28]. Briefly, tracheal tissue was digested
with 1.4 mg/ml Protease type XIV (Sigma) in minimal
essential media at 4°C for 24–48 hours. After digestion,
tracheal epithelial cells were pelleted, rinsed with mini-
mal essential medium, resuspended in LHC-9 media [20]
with 10% fetal bovine serum and 10% dimethylsulfoxide,
and stored in cryovials in a liquid nitrogen freezer.
Tracheal basal cell culture
Primary tracheal basal cells were expanded in LHC-9
media containing 50 μg/ml gentamycin, 1 unit/ml penicil-
lin, 1 μg/ml streptomycin, and 1.25 μg/ml amphotericin B,
and additional supplements as described [20], on plastic
Petri dishes coated with 48 μg/ml PureCol (Advanced
BioMatrix) diluted in 0.01 N hydrochloric acid. Cells were
grown at 37°C in a 5% CO2 incubator, and media was
changed every other day. To subculture basal cells, cells
were treated with 0.025% trypsin/EDTA, which was sub-
sequently neutralized with an equal volume of Trypsin
Neutralizing Solution (Lonza).
Xenografts
Rat tracheal xenografts were performed as described
[29,30] with the approval of the UHN Animal Care
Committee. Briefly, the endogenous epithelium from adult
rat tracheas was removed by three rounds of freeze/thaw.
1 × 106 primary human tracheal basal cells were seeded
per trachea, and one tracheal cassette was implanted sub-
cutaneously onto the back of a single adult male NOD/
SCID mouse. After implantation, tracheas were irrigated
once per week with Ham’s F-12 media, and after three
weeks, were irrigated twice per week. Tracheas were har-
vested between five to eight weeks after transplantation.
Immunofluorescence, histology, and
immunohistochemistry
For immunofluorescence staining of primary tracheal
basal cell cultures, basal cells were cytospun onto chargedglass slides and fixed in 4% paraformaldehyde for 10 mi-
nutes at room temperature. Following fixation, excess
paraformaldehyde was quenched by three five minute
washes in 100 mM glycine/PBS. Cells were permeabilized
with 0.1% Triton X-100/PBS, blocked with 3% bovine
serum albumin (BSA)/0.1% Triton X-100/PBS for 30 mi-
nutes at room temperature, and then incubated with pri-
mary antibody diluted in 3% BSA/0.1% Triton X-100/PBS
for one hour at room temperature. Primary antibodies
were α-KRT5 (ab24647, Abcam, 1:100), α-TP63 (sc-56188,
Santa Cruz, 1:100), α-MUC5AC (MS-145-P1, Neomar-
kers, 1:100), α-MUC16 (sc-33344, Santa Cruz, 1:100), and
α-BTUB4 (T7941, Sigma, 1:100). After primary antibody
incubation, cells were washed three times with 0.1%
Triton X-100/PBS and incubated with secondary antibody
in 3% BSA/0.1% Triton X-100/PBS for two hours at room
temperature or overnight at 4°C. Secondary antibodies
were Alexafluor 488 goat anti-rabbit (Invitrogen, 1:500) and
Alexafluor 568 goat anti-mouse (Invitrogen, 1:500). After
secondary antibody staining, cells were washed three times
with 0.1% Triton X-100/PBS and mounted in Vectashield
mounting media containing DAPI (Vector Laboratories).
Human tracheal and rat tracheal xenograft tissue were
fixed in 10% buffered formalin overnight at room
temperature, then soaked in 70% ethanol overnight at
room temperature, and then paraffin embedded. Paraffin
blocks were cut into 8 μm sections, placed on positively
charged glass slides, and then dried at 55°C overnight.
For immunofluorescence staining, sections were depa-
raffinized through successive incubations in xylene and
decreasing concentrations of ethanol and antigens were
retrieved in 10 mM citrate buffer, pH 6.0, using the 2100
Retriever (Aptum Biologics, Ltd.). Hematoxylin/eosin stain-
ing was performed using standard methods. Anti-MST1R/
RON (Santa Cruz, sc-322, 1:400) immunohistochemistry
was performed using the Vantana Benchmark XT autostai-
ner with the iVIEW DAB detection kit (Vantana Medical
Systems). Images were captured using an Axioimager Z1
microscope and either an AxioCam MRm camera with
Axiovision software (Zeiss) or a Canon EOS color camera.
Fluorescence In Situ Hybridization (FISH) to detect hu-
man DNA in xenografted rat tracheal epithelia was per-
formed on paraffin-embedded tissue using the human
specific CEP3 Alpha Satellite DNA Spectrum Orange probe
(Abbott Molecular) and the manufacturer’s instructions.
High-throughput antibody screen and FACS
Primary human tracheal basal cells were expanded on
plastic until ~70% confluent (7–10 days), removed with
0.025% trypsin, incubated with trypsin neutralizing solu-
tion, and then pelleted and resuspended in FC buffer
(Hanks buffered salt solution with 1% fetal bovine
serum). In control experiments with antibodies that de-
tected heterogeneously expressed markers, we found
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epitopes that were trypsin-sensitive (Additional file 1:
Table S3). Furthermore, this sensitivity was seen with a
two-fold higher concentration of trypsin (0.05%), and
was only partial, with marker expression reduced 2-3-
fold. Thus, our trypsinization conditions did not have a
major effect on marker detection. High-throughput
staining and analysis were generally performed as
described [31]. 50,000 tracheal basal cells in 100 μl were
aliquoted per well into round-bottom 96-well plates, with
each well containing a 2X concentration of each of 334
different fluorochrome-conjugated cell-surface targeted
antibodies (PE, FITC, or APC; see Additional file 2: Table
S1 for vendors). Wells containing buffer only were in-
cluded as negative controls. The final antibody dilution
was 1:50 for all antibodies. Staining was performed on ice
for 20 minutes, after which plates were centrifuged, buffer
aspirated, and pellets washed twice with 200 μl of FC
buffer. Finally, pellets were resuspended in 100 μl of FC
buffer containing 1 μg/ml of DAPI to allow exclusion of
dead cells. Cells were then analyzed on a BD LSRII
equipped with a high throughput sampler. A minimum of
10,000 events per well were collected using FACSDiva
software, and resulting FCS 3.0 files exported to FlowJo
version 9.3 for analysis. Debris, dead cells (DAPI-positive),
and live cell doublets were excluded from analysis by
using the gating strategy outlined in Additional file 3:
Figure S1. Validation experiments were either performed
in a high-throughput manner (with Strain 37) or a single
tube format. For single tube staining, approximately
2 × 105 cells were stained in 100 μl of FC buffer with a
1:50 dilution of the test antibody. Alternatively, α-CD45-
APC (555485, BD Pharmingen) and α-CD326/EpCAM-
FITC (sc-66020, Santa Cruz) were used at 1:10 and 1:25, re-
spectively. CD44 was detected with α-CD44 (14-0441-81,
eBioscience, 1:50) and goat α-mouse-APC (BD Pharmingen,
1:500).
Human protein atlas images
Images were downloaded from the online resource at
www.proteinatlas.org. Antibodies used in the downloaded
images included EGFR (Zymed, 28–0005), MST1R/RON/
CD136 (SDIX, 1659.00.02), PDPN (MBL, D189-1), CD6
(Santa Cruz, sc-65249), CD9 (Novocastra, NCL-CD9),
CD49C (Sigma, HPA008572), CD51 (Novocastra, NCL-
CD51), CD54 (Sigma, HPA004877), CD55 (Sigma,
HPA024386), CD66C (Sigma, HPA011041), CD71 (Zymed,
13–6800), CD91 (Sigma, HPA022903), CD99 (Dako
Cytomation, M3601), CD116 (Santa Cruz, sc-21764),
CD117 (Dako/Cytomation, A4502), CD138 (Sigma,
HPA006185), CD142 (Santa Cruz, sc-20160), CD146
(Novocastra, NCL-CD146), CD226 (Sigma, HPA015715),
CD227 (Dako Cytomation, M0613), CD268 (MBL, D201-3),
CD276 (Sigma, HPA009285).Gene expression analysis
To examine surface marker gene expression in cultured,
normal human bronchial basal cells, microarray gene ex-
pression data were downloaded from GEO (http://www.
ncbi.nlm.nih.gov/geo/) (accession number: GSE24337)
[18]. All of the surface markers that were expressed in
three or more isolates of basal cells (Additional file 6:
Table S2), as well as all of the markers representing recep-
tors for cleaved or secreted factors (Table 1), were selected
for mRNA expression analysis. Surface marker genes
were mapped to Affymetrix probes using ArrayTrans
(http://www.ocigc.ca/arraytrans/). 111/119 of these mar-
kers could be mapped to microarray probes. mRNA ex-
pression values were log normalized, and for each gene,
the probe data with the largest expression value was used.
A Pearson’s product moment correlation coefficient was
then used to test for association between mRNA expres-
sion for a given marker and its average frequency in the
population of normal basal cells (as determined by FACS).
To examine surface marker gene expression in pri-
mary lung cancers, RNAseq data (Tier 3) for adeno-
carcinomas and squamous cell carcinomas from The
Cancer Genome Atlas were downloaded from cBioportal
(http://www.cbioportal.org) [32]. For this analysis, 110
out of the above 119 markers could be mapped to genes
in the RNAseq data. Log quantile normalized RSEM
values were used for testing differential expression bet-
ween the two cell types, and a Bonferroni correction was
used to adjust p-values for multiple testing.
Validation of alamarBlue growth assay and test of
mitogenic activity of MST1/MSP
AlamarBlue was purchased from Life Technologies and
used according to the manufacturer’s instructions. Cell
cultures were incubated with alamarBlue for four hours
at 37°C, after which the red fluorescence of the cellularly
reduced resorufin was measured in the media with a
plate reader at 555/570 nm. To determine the corre-
lation between alamarBlue readings and cell number,
passage one (P1) human tracheal basal cells were seeded
in duplicate in 12-well dishes at 2500 cells/cm2. At days
1, 3, 5, and 7, alamarBlue readings were taken, after
which the cell number was determined by staining cells
with SYTO 60. Multiwell dishes were photographed on
an inverted Olympus IX81 microscope with a 10× ob-
jective lens using a Rolera MGi Plus camera (QImaging)
and MetaMorph software (Molecular Devices). The aver-
age number of cells in the field was determined from
photographs of duplicate wells and was used as an ap-
proximation of cell growth. MST1/MSP was purchased
from R&D Systems and was dissolved in PBS. For
MST1/MSP growth assays, passage one (P1) human tra-
cheal basal cells were seeded at 1000 cells/cm2 in trip-
licate in 6-well dishes. Positive control cultures were
Table 1 Signaling receptors responding to secreted or cleaved factors that are expressed on human tracheal basal cells
Marker Receptor Ligand Mean frequency of positive cells
CD136 MST1R/RON MSP 99.8
CD95 FAS TNFSF6/FASLG 99.5
CD222 IGF2R IGF2 99.0
CD221 IGF1R IGF1 98.2
CD340 ERBB2 EGF 97.7
CD119 IFNGR1 IFNg 97.1
EGFR EGFR EGF 95.6
CD261 TNFRSF10A TNFSF10/TRAIL 87.1
CD262 TNFRSF10B TNFSF10/TRAIL 86.2
CD264 TNFRSF10D TNF 66.4
CD271 NGFR NGF, BDNF, NT-3, NT-4 53.9
CD130 IL6ST (coreceptor for IL6R, LIFR) IL6, LIF 43.6
CDW218a IL18R1 IL18 22.5
CD181 CXCR1 IL8 19.2
CD132 IL2RG (coreceptor for IL7RA, IL9R) IL17A, IL9 18.7
CD295 LEPR Leptin 10.0
CD117 CKIT SCF 3.79
CDW198 CCR8 TARC, MIPb 2.23
CD193 CCR3 CCL11, CCL26, CCL7, CCL13, CCL5 1.84
CD126 IL6R IL6 1.49
CD266 TNFRSF12A TNFSF12 1.08
CD304 NRP1 SEM3A, VEGF-165, PLGF-2 1.01
CD195 CCR5 MCP2, MIP-1a, MIP-1b, CCL5 0.656
CD182 CXCR2 IL8 0.643
CD218b IL18RAP IL18 0.557
CD120b TNFRSF1B TNFSF2/TNFa, TNFSF1/LTA 0.537
PAC1 ADCYAP1R1 PACAP-27, PACAP-38 0.517
CD129 IL9R IL9 0.459
CD184 CXCR4 CXCL12 0.447
CD120a TNFRSF1A TNFSF2/TNFa, TNFSF1/LTA 0.318
CD217 IL17RA IL17A 0.232
CD309 KDR/VEGFR2 VEGF 0.196
CD118 LIFR LIF 0.169
Potential ligands for the receptors were assigned using information at www.genecards.org. Mean frequencies of positive cells are from Additional file 2: Table S1.
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were grown in LHC-9 medium lacking 5 ng/ml EGF and
100 μg/ml BPE. Cells were fed with fresh medium and
growth factor every other day beginning at day 1, at
which point alamarBlue readings were also taken.
Results
Derivation of primary cultures of human tracheal basal
cells
To examine expression of hundreds of cell surface re-
ceptors at a single cell level in human tracheobronchialbasal cells, we chose a FACS-based approach using well
characterized FACS antibodies, which would be more ef-
ficient than optimizing tissue staining for hundreds of
antibodies. The basal cells were extracted from healthy
adult human tracheal tissue (Figure 1A) using previously
described methods [27,28,30,33]. Although our goal was
to profile basal cell surface marker expression in as close
to an in vivo setting as possible, we found that effective
isolation of these cells from tissue required pronase di-
gestion, which appeared to cleave some surface markers
including the canonical basal cell marker CD44 [2,4].
Figure 1 Primary human tracheal epithelial cell cultures are pure populations of basal cells. Primary human tracheal epithelial cells
growing on plastic were cytospun onto glass slides and stained with the indicated antibodies (B-G). Staining of control human tracheal tissue
(A, H-J). (K) Quantification of lineage marker expression in human tracheal basal cell isolates derived from different donor tracheas. For each
strain, 300–800 cells were scored. Mean frequencies ± standard deviations between the strains are shown. Scale bars are 50 μm.
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was determined in individual live tracheal cells with the
general gating strategy outlined in Additional file 3:
Figure S1. Anti-CD44 FACS analysis of tracheal cell sus-
pensions derived from fresh pronase-digested tissue
identified fewer than the expected number of basal cells
(predicted to be ~30% by previous studies [16,34] and
empirically determined by us using anti-TP63 staining)
(Additional file 7: Figure S2). Furthermore, the CD44-
positive cells in these suspensions had a lower overall
fluorescence intensity than control basal cells that had
recovered in vitro and were removed with trypsinization
(Additional file 7: Figure S2). To circumvent the pronase
problem and increase the yield of cells for high-
throughput surface marker profiling, we transiently ex-
panded pronase-digested tracheal suspensions over 7–10
days without passaging. By potentially mimicking aninjury state, this approach also had the advantage of pos-
sibly expanding subpopulations of basal cells that might
be rare in a quiescent epithelium in vivo. During this
time, tracheal cells were grown in a serum-free medium
that is known to support tracheobronchial stem cell/pro-
genitor activity [20,26]. After expansion, cells were re-
moved with a mild trypsinization protocol, which we
found cleaved few surface markers (see below and later).
The purity of the expanded primary tracheal cell cul-
tures was first assessed by antibody staining for intracel-
lular epitopes on canonical basal cell and differentiated
columnar cell markers. 99% and 97% of the cells stained
positive for the basal cell markers KRT5 and TP63,
respectively (Figure 1B,C,K), while none of the cells
stained positive for BTUB4, a ciliated cell marker [35],
or MUC5AC and MUC16, tracheal mucinous cell markers
[36,37] (Figure 1E-K). By FACS, 100% of the cells were
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CD44-positive cells were not hematopoietic since none of
the tracheal cells stained positive for the pan leukocyte
CD45 marker [38] (Additional file 8: Figure S3B) using an
anti-CD45 antibody clone that recognizes a trypsin-
insensitive epitope [39]. In contrast, ~100% of cells from
a control hematopoietic cell line were positively stained
with the same anti-CD45 antibody (Additional file 8:
Figure S3B). These data indicate that our primary tracheal
cultures comprise only basal cells. KRT14, which is hete-
rogeneously expressed in human and mouse large airway
basal cells in vivo [11,13], was also expressed heteroge-
neously in the ex vivo cultures (Figure 1D,K) as reported
in other ex vivo work [13], providing evidence for reten-
tion of some in vivo heterogeneity ex vivo.
Verification of functional stem cell/progenitor activity in
primary tracheal basal cell cultures
We next verified that our primary human tracheal basal
cell cultures maintained functional stem cell/progenitor
activity. It has been reported that with the isolation and
expansion conditions we used, human tracheal basal
cells retain multipotentiality, as revealed in rat trachealFigure 2 Conditions that support expansion of primary human trache
Expanded, primary P0 human tracheal basal cells were enzymatically remov
five weeks, mucociliary differentiation in xenografts was assessed morpholo
transplanted rat tracheal xenograft not seeded with human basal cells. (C)
detect cells of human origin. Insets show magnified areas of positivity in xe
bars are 20 μm.xenograft assays [8]. In this assay, human tracheal basal
cells are seeded into denuded rat tracheas and implanted
as xenografts onto the backs of immunocompromised
mice [8,30]. This assay is one of the most stringent as-
says for human tracheal stem cell activity. It allows for
the generation of the most in vivo-like pseudostratified
mucociliary epithelium, and it uniquely allows assess-
ment of submucosal gland lineage potential [8]. To
verify that our primary tracheal basal cell culture condi-
tions maintain stem cell activity, we assessed the ability
of basal cells derived from two different donor tracheas
to repopulate denuded rat tracheas. After five weeks,
engrafted primary tracheal basal cells gave rise to mor-
phologically well-differentiated mucociliary epithelia and
occasional submucosal glands (Figure 2). These epithelia
and glands did not form in the absence of transplanted
cells (Figure 2A), closely resembled their counterparts in
normal human tracheal tissue (Figures 1A and 2B, C-E),
and were of human origin, as assessed by FISH for a
human-specific centromeric probe (Figure 2F). Thus,
our isolation and culture conditions generally support
the ex vivo expansion of tracheal basal cells capable of
giving rise to multiple differentiated lineages.al basal cells maintain mucociliary differentiation activity.
ed from plastic dishes and grown as rat tracheal xenografts. After
gically by H/E staining of tissue sections (A, B, D-F). (A) Control
FISH with a human-specific chromosome 3 centromeric probe to
nografted epithelia (white), but not underlying stroma (green). Scale
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molecularly distinct subpopulations of human tracheal
basal cells
To investigate expression of cell surface receptors at a
single cell level and to identify new signaling pathways
that potentially modulate tracheobronchial basal cell be-
havior, we used flow cytometry to profile expression of
332 surface markers in primary, non-passaged human
tracheal basal cell cultures. Human tracheal basal cells
derived from two different donor tracheas were stained
and analyzed by FACS in a high-throughput manner.
314 out of the 332 tested antibodies yielded good quality
FACS data in both basal cell strains (Additional file 2:
Table S1). 108 of these antibodies stained less than 0.1%
of the total population in both strains of basal cells, which
we set as a cut-off for detectable expression (Additional
file 2: Table S1). They provided a large number of isotype
controls that indicated basal cells are not generally “sticky”
to all antibodies. Some of these antibodies included anti-
CD31, which is commonly used to detect endothelial cells
[40], as well as three different anti-CD45 antibodies
(Additional file 2: Table S1), and support our earlier fin-
dings that our tracheal cell cultures are not contaminated
with non-basal cell types. 157 markers were detected in
both basal cell strains and were expressed on varying
numbers of cells (Table 2). These shared markers re-
presented 80% and 95% of all expressed markers in
each strain, indicating an overall strong similarity in the
immuno-surface phenotype between the strains (Table 2).
To further confirm the epithelial origin of rarer subpopu-
lations of tracheal cells, we co-stained primary tracheal
cell cultures with antibodies to a few of these markers,
as well as CD45 and CD326/EpCAM. CD326 is only
expressed in epithelial cells, including bronchial epithelial
cells [41,42]. By gating on cells that were CD326-positive
and CD45-negative, we confirmed that these rare sub-
populations are indeed, epithelial (Figure 3).
We then chose to validate 110 of the shared expressed
markers in one or two additional basal cell strains de-
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markers from strain 23 that are expressed (or not expressed, <0.1%) in the same inTable S1). These validation strains did not have detec-
table contamination with CD31 or CD45-positive cells
(Additional file 2: Table S1). 105 of the 110 basal cell
markers were detected in these additional strains, identi-
fying a large set of markers expressed in three to four in-
dependently isolated basal cell strains. The high degree
of validation (95%) suggests that most of the markers
identified as being shared between the initial screening
strains can be extended to all isolates of human tracheal
basal cells. Within the group of 105 markers, 74 were
expressed with a mean frequency of less than 90%
(Additional file 6: Table S2), suggesting that they are
heterogeneously expressed within the basal cell bulk
population. Heterogeneous expression of these markers
(especially low expression) was not due to our mild tryp-
sinization protocol. Prior control studies indicated that
the anti-CD31 and anti-CD45 antibodies, as well as most
of the antibodies to the heterogeneously expressed mar-
kers recognize trypsin-insensitive epitopes [31] (sum-
marized in Additional file 1: Table S3). In these control
experiments, a cocktail of collagenase, hyaluronidase, dis-
pase, and a two-fold higher concentration of trypsin only
affected FACS detection of 17 of 68 tested markers of het-
erogeneity. Furthermore, of these 17 markers, detection of
only three (CD62L, CD195, CD213a2, 4.4% of number
assayed) was affected by trypsin in isolation. Since expres-
sion of these three markers was only affected two to
three-fold while their mean frequencies in the bulk basal
cell population ranged from 0.6-3.7%, even partial sen-
sitivity to trypsin cannot account for their heterogeneous
expression. For 47 markers, mean frequencies were mea-
sured between 0.1 to <90% of the total basal cell popula-
tion with 95% confidence (Additional file 6: Table S2),
identifying good candidates for heterogeneously expressed
markers. Examples of representative FACS plots for these
markers are shown in Figure 4. Some markers displayed a
lot of variation in the number of positive cells in different
basal cell isolates, while others, especially those expressed
on fewer than 6% of all basal cells, were detected at con-
sistently similar frequencies (Additional file 6: Table S2).man tracheal basal cells derived from different tracheas
Overlap of markers between strains
rainsa Strain 23b Strain 38c Validation strains
108 (73%) 108 (92%)
40 (65%) 40 (46%)
23 (68%) 23 (53%)
66 (94%) 66 (97%)
85 (89%) 85 (66%)
157 (95%) 157 (80%) 105 (95%)
sal cells that were not used in the initial high-throughput screens. bNumber
0.1%) in the same indicated category of strain 23. cNumber and (percentage) o








































































Figure 3 Rare subpopulations of human tracheal cells are epithelial. Primary human tracheal cells were triple stained for the epithelial-specific
marker CD326/EpCAM (α-CD326-FITC), the hematopoietic-specific marker CD45 (α-CD45-APC), and the marker of interest (PE-conjugated). The epithelial
cells in the triple-stained population were first identified by applying a CD326-positive/CD45-negative gate (A). A PE-positive gate was created after
compensation with the appropriate FMO controls to account for overlap between FITC and PE channels, and was applied to the CD326-positive/
CD45-negative cells in the triple-stained populations shown in (B). (B) Identification of PE-marker-positive cells in the CD326-positive/CD45-negative
fraction of human tracheal cells.
Van de Laar et al. Respiratory Research  (2014) 15:160 Page 9 of 22By looking at marker frequencies with non-overlapping
95% confidence intervals, it appeared that using several
different cut-offs, subpopulations of basal cells could be
grouped into more (e.g. ~ > 13%) or less (e.g. ~ < 6%)
abundant subpopulations (see Figure 5A for examples).
While a complete analysis of the total number of
subpopulations represented by marker heterogeneity was
beyond the scope of this work, we, nevertheless, investi-
gated potential overlap between some subpopulations.
CD90-expressing cells (~3% of the total population) did
not overlap with CD36L1 (0.75%) or CD227 (1.31%)-
positive cells, indicating that CD90-positive cells are
distinct from these other subpopulations (Figure 5B).
Furthermore, CD36L1 and CD227 did not markidentical subpopulations since >90% of CD36L1, but
only 12% of CD227-positive cells expressed CD66c
(Figure 5C).
Microarray corroboration of basal cell surface marker
expression
To corroborate the surface marker heterogeneity observed
by FACS by another method, we investigated if marker
FACS data correlated with marker mRNA expression in
the bulk population. We focused on the 105 surface
markers that were validated in three or more basal cell
isolates (Additional file 6: Table S2), as well as 14
additional signaling receptors that were not analyzed by
FACS beyond the initial high-throughput screening (part























































































Figure 4 Examples of FACS plots for cell surface markers that are heterogeneously expressed on tracheal basal cells. Primary human
tracheal basal cells were stained with PE-conjugated antibodies for the indicated markers. FACS staining for strains 23 and 38 were done at the
same time using the same control unstained cells and therefore, have the same gates. FACS staining for strain 37 was done at a different time
and the gates for this strain are drawn relative to the unstained controls used at that time.
Van de Laar et al. Respiratory Research  (2014) 15:160 Page 10 of 22of Table 1). mRNA levels were determined from five
microarray datasets of gene expression in primary human
bronchial basal cells that were grown under the same
culture conditions used by us [18]. Probes for 111/119
markers were on the microarrays yielding 92% coverage.
Overall, we found that the percentage of marker-positive
cells detected by FACS was correlated with mRNA expres-
sion for that marker (Figure 6A). These data corroborate
the accuracy of the antibodies in detecting their antigens,
and support the FACS data indicating basal cells exist as
distinct, molecularly identifiable subpopulations. We also
found that in the microarray analysis [18], 21/111 of our
markers were independently annotated as basal cell-
enriched genes relative to the other large airway epithelialcells (Figure 6B). These data additionally suggest that a
number of our markers are not only expressed on basal
cells, but also define basal cell lineage-specific markers.
In vivo expression of basal cell surface markers in normal
airway tissue
To determine if some of the basal cell markers we
identified in vitro might mark basal cells in normal
airway tissue in vivo, we used the Human Protein Atlas
(www.proteinatlas.org), which is an expansive online re-
source for normal and cancer tissue immunostaining for
the human proteome [43-47]. Normal tissues included
the nasopharynx and bronchus, which share the same



























































































































































Figure 5 Subpopulations of tracheal basal cells vary in their abundance. (A) Histogram showing subpopulations with overlapping and
non-overlapping 95% confidence intervals of mean frequency in the total population. Data are from Additional file 6: Table S2 and represent a
subset of markers. (B, C) Analysis of potential dual expression of a subset of heterogeneously expressed markers in tracheal basal cells. Primary
human tracheal basal cells were stained with FITC and PE-conjugated antibodies for the indicated markers. Gates were created after compensation
with the appropriate FMO controls to account for overlap between FITC and PE channels.
Van de Laar et al. Respiratory Research  (2014) 15:160 Page 11 of 22were available for 83 of the 105 markers we identified in
three or more basal cell isolates. 63 of these markers
showed some expression in airway epithelia. Expression
ranged from all epithelial cells to exclusively all basal
cells, to only subsets of basolaterally located cells (but
not necessarily, basal epithelial cells). By using the trad-
itional morphological criteria that were used to establish
basal cell-specific expression of the canonical basal cell
markers (cuboidal shape and occupying exclusively and
uniformly basolateral positions) KRT5, KRT14, CD44,
and GSA-I-B4 reactivity [3,4,48-50], it appeared that
CD55, CD49C, CD276, CD146, CD9, CD142, and theEGFR, which were detected on most basal cells in vitro,
were also expressed on most basal cells in vivo (Figure 7).
While PDPN, CD91, CD138, and possibly CD51, also
appeared to be enriched on most basal cells in vivo
(Figure 9), in vitro, these markers were expressed only on
subsets of basal cells. Collectively, these eleven markers
identify pan-basal cell lineage markers. CD54, CD227,
CD99, and possibly CD6, were expressed heteroge-
neously in vitro and at basolateral positions in vivo
(Figure 7). However, in these cases, it is not clear if
































































































































in Basal cells in Basal cells
Marker Gene (FACS)a (mRNA)b
CD73 NT5E 99.8 7.93
CD104 ITGB4 99.8 9.63
CD49c ITGA3 99.7 15.9
CD146 MCAM 99.6 12.0
CD29 ITGB1 99.6 7.18
CD49e ITGA5 99.6 27.3
CD49f ITGA6 99.5 50.8
CD222 IGF2R 99.0 5.10
CD141 THBD 95.7 31.5
EGFR EGFR 95.6 10.2
CD261 TNFRSF10A 87.1 5.11
CD262 TNFRSF10B 86.2 15.3
CD44 CD44 86.2 8.42
CD264 TNFRSF10D 66.4 15.3
CD201 PROCR 56.7 33.1
CD295 LEPR 9.95 7.15
CD36L1 SCARB1 5.46 7.61
CD138 SDC1 2.16 8.51
CD266 TNFRSF12A 1.08 25.5
CD304 NRP1 1.01 12.5
CD213a2 IL13RA2 0.63 200.8
Figure 6 Comparison of large airway basal cell marker
expression by FACS and mRNA analysis. (A) Scatter plot
comparing the frequency of cell surface marker expression with
corresponding marker mRNA expression in bulk population basal
cells. The average percentage of marker expression was taken from
Additional file 6: Table S2 and mRNA data were from Hackett NR
et al., PLoS One, 2011. The mRNA expression data represent the
average of five replicate microarray hybridizations, with the value
for the most highly expressed probe for a given gene being
plotted. The red line shows the linear relationship between the two
properties (Pearson correlation r = 0.67; t = 7.85; p-value < 0.001).
(B) Table of marker genes that were determined to be more than
5-fold enriched at the mRNA level in basal cells relative to other
large airway epithelial cells. mRNA data are from Hackett NR et al.,
PLoS One, 2011, and are from the most highly expressed probe for
the gene.
Van de Laar et al. Respiratory Research  (2014) 15:160 Page 12 of 22In vivo expression of basal cell surface markers in lung
squamous cell carcinomas
To further support the in vivo relevance of the new basal
cell markers and to begin to explore their potential rele-
vance to cancer biology, we also examined marker ex-
pression in squamous cell lung cancers (SQCCs), which
likely arise from basal cells. SQCCs develop in the large
airways and >90% of SQCCs express pan-basal cell
lineage markers such as KRT5 and TP63 [51,52]. To
strengthen the interpretation that some SQCC marker
expression reflects the basal cell origin of SQCCs, we
also examined marker expression in control lung adeno-
carcinomas (ADCs), most of which are not likely to arise
from basal cells. ADCs tend to develop distally, with
KRT5 and TP63 expression being infrequent [51,52]. For
this analysis, we used the same panel of 119 markers
that was employed in the microarray analysis. 110 of
these markers could be mapped to genes in The Cancer
Genome Atlas lung cancer RNAseq datasets [32]. 22%
(24/110) of these markers had significantly higher ex-
pression (p-value < 0.05) in SQCCs compared to ADCs
(Additional file 4: Table S4, Figure 8). This degree of
enrichment is much larger than expected by chance, as
using the same statistical analysis and threshold for sig-
nificance (p-value < 0.05), only 1.4% (290/20,725) of total
genes was estimated to be significantly upregulated in
SQCCs relative to ADCs. The degree of basal cell
marker enrichment in SQCCs was also greater than ob-
served for 101 control markers not expressed on basal
cells (expressed on <0.1% of all basal cells) (7%, Additional
file 5: Table S5, Figure 1). In this latter case, the 7% en-
richment is likely an overestimate of true enrichment due
to the misclassification of some markers as being not
expressed on basal cells. Some FACS antibodies may have
yielded false negative results due to their inability to
recognize all protein isoforms and their modified variants
for a given gene. Notably, among the control markers, the
two most SQCC-enriched proteins, JAG1 and FGFR2,
were not detected on basal cells by FACS, but by mRNA
Figure 7 Expression of a subset of FACS-identified cell surface markers in vivo. Human nasopharyngeal (CD55, CD49C, CD276, CD146, EGFR,
PDPN, CD91, CD138, CD54, CD227, CD99, CD6) or bronchial (CD9, CD142, CD51) tissue was stained with the indicated antibodies. Images are
from The Human Protein Atlas online resource (www.proteinatlas.org). Scale bars are 50 μm.
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human airway basal cells growing in vitro and in vivo
[18,53-55].
While the fold-differences in marker mRNA expression
between the SQCCs and ADCs were not dramatically dif-
ferent, many of these differences are likely to be meaning-
ful at the protein level. Protein expression of 14/24 of the
SQCC-enriched markers has been detected in SQCCs
[56-67], and at least in seven cases (CD98/SLC3A2, CD44,
CD221/IGF1R, CD276, CD141/THBD, EGFR, PDPN),
marker protein expression was reported to be greater
or more common in SQCCs as compared to ADCs
[58,62-66,68-70]. Furthermore, expression of three markers
has been reported to be prognostic with regards to
overall survival in SQCCs (CD98/SLC3A2, CD44, PDPN)
[60,63,71-73]. To obtain protein data to corroborate the
mRNA data for the remaining SQCC-enriched markers notpreviously interrogated in SQCCs, we examined marker
protein expression in lung cancer samples through the
Human Protein Atlas (www.proteinatlas.org). While the
small number of cancer samples did not allow assessment
of statistical significance, several of the new markers
identified through mRNA analysis also showed trends
of increased protein expression in SQCCs relative to
ADCs (CD71/TFRC, CD9, PDPN, CD138/SDC1, CD99)
(Figure 9, Additional file 9: Table S6). Using the Human
Protein Atlas, we also found that some of the heteroge-
neously expressed basal cell markers that were not identi-
fied as SQCC-enriched markers, were, nevertheless, still
expressed in SQCCs (Figure 9, Additional file 9: Table S6,
CD227/MUC1, CD54/ICAM1).
Since some of the SQCC-enriched markers have already
been shown to have prognostic significance to SQCCs
[60,63,71-73], we examined the remainder of these








































ITGAV − CD51 (2.49%)
ITGA2 − CD49B (99.87%)
CD99 − CD99 (1.86%)
SIRPA − CD172a (83.00%)
IGF2R − CD222 (98.95%)
SDC1 − CD138 (2.16%)
EGFR − EGFR (95.60%)
LTBR − LTBR (94.20%)
MME − CD10 (20.20%)
THBD − CD141 (95.70%)
IL17RA − CD217 (0.23%)
ITGA5 − CD49E (99.57%)
SCARB1 − CD36L1 (5.46%)
TNFRSF13C − CD268 (8.03%)
F11R − CD321 (99.60%)
ITGB4 − CD104 (99.80%)
CD276 − CD276 (99.60%)
IGF1R − CD221 (98.20%)
PDPN − PDPN (65.90%)
CD44 − CD44 (86.20%)
SLC3A2 − CD98 (99.70%)
CD9 − CD9 (97.80%)
NGFR − CD271 (53.90%)
ITGA6 − CD49f (99.50%)





















































Figure 8 Enrichment of basal cell surface markers in lung squamous cell carcinomas. Heat map of mRNA expression in lung adenocarcinomas
(ADCs) and squamous cell carcinomas (SQCCs) for the top 25 SQCC-enriched markers from those detected (Additional file 4: Table S4) or not detected
(Additional file 5: Table S5) on tracheal basal cells by FACS. For each marker, the normalized log RSEM value for mRNA expression in each sample was
scaled according to the distribution across samples. The percentage shown beside each marker name indicates the mean frequency of marker
detection in bulk population tracheal basal cells (from Additional file 2: Table S1).
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survival by Kaplan Meier survival analysis. We used KM-
plotter (http://kmplot.com/analysis/) [74], an online re-
source that compiles gene expression and overall survival
data from the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas
(http://cancergenome.nih.gov/). Using the entire SQCC
and ADC datasets, we found that expression of four
markers had significant associations with overall SQCC
patient survival (Figure 10). Two markers were associated
with worse overall survival (CD49E/ITGA5, CD141/
THBD) and two markers were associated with better over-
all survival (CD49F/ITGA6, CD222/IGF2R). For CD141/
THBD and CD49F/ITGA6, the direction of the asso-
ciation with overall survival was unique to SQCCs. This
finding could relate to these markers having different
functions in SQCCs and ADCs and their distinct cells oforigin. CD49E/ITGA5 and CD222/IGF2R were prognostic
in the same direction in both SQCCs and ADCs, sugges-
ting that despite elevated expression in SQCCs, these pro-
teins may perform similar functions in the two tumor
types and their cells of origin. Collectively, these normal
and tumor tissue data support the relevance of our newly
identified markers to in vivo populations of normal and
transformed basal cells.
MST1/MSP stimulates proliferation of tracheal basal cells
Among the surface markers detected on human tracheal
basal cells were 33 receptors that are involved in sig-
naling by cleaved or secreted factors (Table 1). Receptors
for EGF, IGF, insulin, NGF, MST1/MSP, IFNγ, FASL, and
some TNF family growth factors were expressed on most
basal cells while receptors for leptin, LIF, VEGF, SCF,
chemokines, interleukins, and other TNF family
Figure 9 Protein expression of basal cell surface markers in lung cancer. Images are from the Human Protein Atlas online resource
(www.proteinatlas.org). Quantification of staining is shown in Additional file 9: Table S6. Scale bars are 100 μm.
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tions suggest that some factors may act on all basal cells
while others may regulate distinct subpopulations. Some
of these receptors are known to be functional as EGF
and insulin are essential components of the serum-free
medium used to culture human tracheal basal cells
[19,20,22] and NGF promotes survival of basal cells
after RSV infection [75].
Since the biological function of most of these recep-
tors is unknown in large airway basal cells, we chose to
investigate one receptor in more detail. CD136/MST1R/
RON is the receptor for MST1/MSP and by FACS, was
expressed on all basal cells (Table 1, Additional file 2:
Table S1). Although a biological function for MST1/
MSP has not been reported in basal cells, it has pre-
viously been shown to directly bind cultured human
tracheal basal cells and to induce phosphorylation of
MST1R/RON [76]. Furthermore, MST1R/RON missense
mutations and expression of an alternatively spliced
oncogenic MST1R isoform have been reported in lung
SQCCs [32,77], suggesting this receptor may promote
growth of basal cells, as it does in TP63-positive kera-
tinocytes [78]. To address this possibility, we cultured
tracheal basal cells in the absence of EGF and bovinepituitary extract, which allowed the cells to remain
viable, but reduced cell growth. We then added two dif-
ferent doses of MST1/MSP and measured cell growth by
alamarBlue, which we found is directly proportional to
cell number (Additional file 10: Figure S4). Both doses of
MST1/MSP promoted growth, with the higher dose
yielding half the maximal cell number obtained with
optimized amounts of EGF and bovine pituitary extract
(Figure 11A). We also verified that MST1R/RON was
expressed in tracheal basal cells in vivo by immunostai-
ning human tracheal tissue with anti-MST1R antibodies.
MST1R/RON expression was detected in all cells of the
tracheal epithelium, including basal cells (Figure 11B).
This expression pattern was corroborated by the Human
Protein Atlas with a different anti-MST1R/RON antibody in
the nasopharyngeal epithelium (Figure 11C), where MST1/
MSP has been reported to increase the beat frequency of
ciliated cells [76]. Thus, MST1/MSP has distinct effects on
basal and non-basal cell types in the large airways.
Discussion
A number of studies have provided evidence for basal
cell heterogeneity in the large airways [3,6,8-12,79], but
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HR = 1.42 (1.09 - 1.85)
logrank P = 0.0094
CD49E/ITGA5
HR = 1.72 (1.28 - 2.30)
logrank P = 0.0094
CD141/THBD
HR = 1.52 (1.17 - 1.99)
logrank P = 0.0019
CD141/THBD
HR = 0.66 (0.49 - 0.89)
logrank P = 0.0051
CD222/IGF2R
HR = 0.67 (0.51 - 0.88)
logrank P = 0.0031
CD222/IGF2R
HR = 0.49 (0.37 - 0.66)
logrank P = 1.70E-06
CD49F/ITGA6
HR = 0.72 (0.55 - 0.94)
logrank P = 0.0151
CD49F/ITGA6
HR = 1.24 (0.93 - 1.65)
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Figure 10 Prognostic significance of basal cell markers enriched in lung squamous cell carcinomas (SQCCs) and adenocarcinomas
(ADCs). Univariate Kaplan-Meier survival analysis was performed using the entire lung SQCC (n = 421) and ADC (n = 487) datasets compiled at
KM-plotter (http://kmplot.com/analysis/) [74]. HR = Hazard ratio (95% confidence interval). HR > 1.00 = poor overall survival. HR < 1.00 = better
overall survival. Affymetrix probes were 201389_at (CD49E/ITGA5), 203887_s_at (CD141/THBD), 201393_s_at (CD222/IGF2R), and 215177_s_at
(CD49F/ITGA6).
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was to specifically investigate heterogeneity among basal
cells using cell surface markers that can help identify/
purify subpopulations and reveal signaling pathways that
regulate their behavior. To this end, we identified 105
cell surface markers that were expressed on varying
percentages of basal cells isolated from three or more
healthy tracheas. Furthermore, the 95% validation rate of
markers detected on the initial two screening strains
suggests that we may have identified as many as 157 sur-
face markers for large airway basal cells. With 95% con-
fidence, 47/105 validated markers were expressed on
between 0.1 to <90% of all basal cells, identifying goodcandidates for heterogeneously expressed markers. This
interpretation of the FACS data was independently sup-
ported by microarray gene expression profiling of large
airway basal cells. Here, we found that mRNA expres-
sion for most markers was proportional to our measure-
ments of the abundance of marker-positive cells in the
bulk basal cell population. However, the total number of
distinct subpopulations is not clear. At a minimum,
subsets of cells can generally be grouped into more (e.g.
>13%) or less (e.g. <6%) abundant subpopulations. Our
analysis of a small set of markers indicate some subpop-
ulations are distinct (e.g. CD90 from CD36L1 and
CD227), while some overlap (e.g. CD66c and CD36L1).
Figure 11 MST1/MSP is a mitogen for tracheal basal cells and
MST1R/RON is expressed in all large airway basal cells in vivo.
(A) The MST1R/RON ligand MST1/MSP promotes growth of human
tracheal basal cells. Growth was measured by the alamarBlue assay.
Each data point represents the mean of triplicate cultures with the
standard deviation shown. p values were calculated for the day 13
data point relative to cells growing in control basal medium without
EGF and BPE, using a two-tailed student’s t test. (B) Human tracheal
tissue stained with anti-MST1R/RON (Santa Cruz). (C) Human
nasopharyngeal tissue stained with anti-MST1R/RON. Image is from
The Human Protein Atlas online resource (www.proteinatlas.org).
Scale bars are 50 μm.
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will be necessary to refine the subclassification of basal
cell subpopulations. The recently developed massspectrometry-coupled single cell flow cytometer, in
which up to 30 parameters can be simultaneously visua-
lized [80], could rapidly deconvolute the complex het-
erogeneity observed in our experiments.
The origin of the observed surface marker heterogen-
eity is not clear. Some markers showed substantial varia-
tions in expression between different basal cell isolates,
which could simply reflect highly variable stochastic re-
sponses to ex vivo culturing. Alternatively, they could re-
flect pre-existing differences in the numbers of these
subpopulations between different donor tracheas, which
might be influenced by age (range was 38–59) or other
factors (although all donors were non-smokers). How-
ever, many markers, especially those expressed on <6%
of all cells, were consistently detected at similar frequen-
cies in all tested basal cell isolates, suggesting that some
subpopulations are under tight control. This might re-
flect the partitioning of some basal cells into more stem/
progenitor-like cells as has been previously suggested
[8,10,13]. Indeed, in co-culture assays, human colony for-
ming progenitors have been estimated between 0.15-0.6%
of all basal cells, while in semi-solid media, the frequencies
have been measured between 0.4-12% [5,9,10]. Consistent
with this possibility, CD338/ABCG2 was found on 0.12-
0.15% of tracheal basal cells (Additional file 2: Table S1).
This marker is the major transporter that is responsible
for the Hoechst 33342 efflux properties that define “side
population” (SP) progenitor cells [81]. Similar to our find-
ings, previous work reported that 0.12% of human tracheal
epithelial cells are ABCG2/TP63-double positive side
population cells, but additionally found that these cells
might have enhanced progenitor activity [82]. Another
one of our markers, CD117/KIT, was reported to mark
embryonic-like multipotential human lung stem cells and
has been reported to be co-expressed with TP63 in rare
bronchiolar cells in vivo [83].
Most of the heterogeneously expressed markers have no
prior association with normal epithelial stem cells. How-
ever, CD66c/CEACAM6 was reported to be a marker of
colorectal cancer stem cells [84] and was also shown to be
heterogeneously expressed in cultured human large airway
basal cells by confocal microscopy [85]. Many other
markers (CD54, CD182/CXCR2, CD193/CCR3, CD90,
CD13) have been reported to be expressed on mesen-
chymal stem cells (MSCs) and are often co-expressed with
markers such as CD166, CD29, CD44, CD73, and CD49B,
which were detected on most tracheal basal cells [86-94].
Given the greater than 99% KRT5 positivity of our cul-
tured tracheal cells, our cultures are not likely contami-
nated with typical MSCs. Instead, we believe that some
surface markers are shared between certain mesenchymal
and tracheal epithelial stem/progenitor cell populations.
Indeed, some liver progenitors are marked with both MSC
and epithelial markers [88,89].
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ging. In general, antibody staining of tissue is more
problematic than FACS staining, and many markers
were detected on rare cells, which can be difficult to dis-
tinguish from hematopoietic cells in tissue, but could be
excluded in our in vitro studies. Furthermore, the dra-
matic differences between the in vivo and in vitro envi-
ronments may affect the steady state levels of certain
subpopulations and expression of some markers. In the
normal in vivo airway epithelium, basal cells are mostly
quiescent and form many adhesive contacts with each
other and a complex extracellular matrix. In vitro, our
basal cells were characterized while proliferating sub-
confluently on a two-dimensional extracellular matrix.
Nevertheless, we confirmed that eleven markers identi-
fied in vitro were strongly enriched in the entire large
airway basal cell compartment in vivo, revealing pan-
basal cell lineage markers. Seven of these eleven markers
were expressed on most basal cells in vitro (CD55,
CD49C, CD276, CD146, CD9, CD142, EGFR), suggest-
ing that their expression is not greatly influenced by the
environment or the proliferative state. Four of these
markers (PDPN, CD91, CD138, CD51) were much more
heterogeneously expressed in vitro than in vivo. PDPN,
CD138/SDC1, and CD51/ITGAV are adhesion molecules
and might be downregulated in vitro because of the 2D
growth conditions, which lack a 3D matrix. Interestingly,
PDPN has been reported to be heterogeneously ex-
pressed among TP63 and CD44-positive cells in lung
SQCCs [63]. Thus, absence of PDPN expression is more
commonly observed under conditions of growth (normal
basal cells in vitro and transformed basal cells in lung
SQCCs) rather than quiescence (basal cells in healthy
large airways). It is, therefore, possible that PDPN ex-
pression may mark a more quiescent basal cell state,
which could explain its correlation with better prognosis
in lung SQCCs [63,71,73]. However, the function or
regulation of PDPN may differ between distinct types of
basal cells since in SQCCs derived from other tissues,
PDPN expression is correlated with poor prognosis
[95,96]. Although some of the markers that were hetero-
geneously expressed in vitro were also heterogeneously
expressed in vivo (e.g. CD54, CD227, CD99, CD6), it is
unclear if these in vivo populations are basal epithelial
cells or hematopoietic cells.
By comparing marker expression in lung squamous
cell carcinomas (SQCCs) and adenocarcinomas (ADCs),
we obtained further evidence for the in vivo relevance of
some of the markers, as well as the basal cell origin of
SQCCs. We identified 24 basal cell markers that were
significantly enriched in SQCCs relative to ADCs. Many
of these markers additionally represent new and poten-
tially useful biomarkers for SQCCs. Based on our in vitro
studies, some of these markers appear to be pan-basal celllineage markers or are at least associated with a prolife-
rative basal cell state. Accordingly, some of the SQCC-
enriched basal cell markers might read-out or contribute
to basal cell functions that promote malignancy (e.g. pro-
liferation). Alternatively, some of the markers might be
remnants of the normal basal properties that oppose a
cancerous state (e.g. adhesion). Consistent with both pos-
sibilities, CD98/SLC3A2 expression was previously found
to be associated with shorter overall survival, while CD44
and PDPN expression was correlated with longer overall
survival [60,63,71-73]. In addition to these markers, we
found that expression of CD49E/ITGA5 and CD141/
THBD was also associated with shorter overall survival,
while expression of CD222/IGF2R and CD49F/ITGA6
was associated with longer overall survival. Interestingly,
in ADCs, CD141/THBD expression was actually asso-
ciated with longer overall survival, while CD49F/ITGA6
was not prognostic. These data suggest that CD141 and
CD49F may have distinct cell of origin and disease-
specific functions.
Some of the SQCC-enriched markers were only de-
tected on subsets of normal basal cells cultured in vitro
(CD268/TNFRSF13C, CD36L1/SCARB1, CD217/IL17RA,
CD10/MME, CD138/SDC1, CD99, CD51/ITGAV) and
possibly found in vivo (CD51, CD99). These data suggest
that the normal subpopulations defined by these markers
might specifically be involved in SQCC pathogenesis. Two
markers of normal heterogeneity (CD54 and CD99) also
appeared to be heterogeneously expressed in SQCCs. In
SQCCs, CD99 expression seemed restricted to less well-
differentiated, basal-like cells. The intratumoral hetero-
geneity of expression of these markers could be relevant
to the cellular hierarchical organization that has been
described in SQCCs with regards to tumor initiating ac-
tivity [97,98].
Finally, besides being molecular markers of phenotypic
diversity, many of the surface antigens we detected
provide new insight into signaling pathways that may
regulate basal cell behavior. This information will be im-
portant to understand how large airway progenitor self-
renewal and differentiation are regulated, how basal cell
homeostasis may be deregulated during disease patho-
genesis, and to ensure subpopulations with distinct
growth factor requirements can be optimally cultured
ex vivo. As a testament to the potential importance of
these signaling pathways, we found that the MST1R/
RON receptor tyrosine kinase was expressed on all tra-
cheal basal cells and that its ligand, MST1/MSP pro-
moted basal cell growth. This function of MST1/MSP
contrasts with its non-proliferative ability to enhance
beat frequency of ciliated cells [76], but is in agreement
with its growth stimulatory role in keratinocytes [78],
suggesting a potentially conserved mitogenic role in
TP63-positive basal cells. This mitogenic function of
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genic splice variants of MST1R/RON in SQCCs and the
occurrence of rare MST1R missense mutations in these
cancers [32,77].
Conclusions
We have identified 105 cell surface markers that are
expressed on cultured primary human tracheal basal cells,
and we provide evidence for 47 of these markers being
heterogeneously expressed in the bulk population. Eleven
markers appear to be pan-basal cell lineage markers
in vivo and 24 markers are enriched in lung SQCCs rela-
tive to ADCs, with four of these markers having prognos-
tic relevance to lung cancer. We also show that some of
these newly identified markers are functional in basal cells,
as MST1/MSP, the ligand for CD136/MST1R/RON, is a
mitogen for basal cells. Overall, this study provides evi-
dence for molecularly distinct heterogeneity within the
human tracheal basal cell population, and it identifies
many new opportunities for the directed investigation of
stem cells/progenitors in the normal tracheobronchial epi-
thelium and in SQCCs.
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data that indicate primary tracheal cell cultures are entirely comprised of
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